Acuta Capital Partners
Overview
Acuta Capital Partners, LLC provides investment management services to Clients. Acuta's investment philosophy is based on bottom-up analysis, absolute-value oriented investing, and a long-term perspective. Acuta intends to employ a value approach to investing that is risk averse and focused on preserving capital over the long run . Acuta invests in securities of small-cap and mid-cap issuers, which may present greater risks than those of large-cap issuers .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Artiva Biotherapeutics | Feb 2021 | Series B | Co-investor |
| Surrozen | Mar 2025 | Private Placement | - |
| Enliven Therapeutics | Mar 2024 | Private Placement | - |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Acuta Capital Partners based?
Acuta Capital Partners is headquartered in Belmont, California, United States.
When was Acuta Capital Partners founded?
Acuta Capital Partners was founded in 2011.
How many portfolio companies does Acuta Capital Partners have?
Acuta Capital Partners has 7 portfolio companies in Caplight's dataset.
What are some companies in Acuta Capital Partners's portfolio?
Portfolio companies visible on Caplight include Artiva Biotherapeutics, Surrozen, Enliven Therapeutics.
What was Acuta Capital Partners's most recent investment shown here?
Acuta Capital Partners's most recent investment in this portfolio sample was in Surrozen in 2025.
What sectors does Acuta Capital Partners focus on?
Acuta Capital Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Enterprise Software.
What company stages does Acuta Capital Partners focus on?
Acuta Capital Partners typically invests at the Mid stage.
What is Acuta Capital Partners's AUM?
Acuta Capital Partners's assets under management are estimated between $100.0M and $250.0M.